相似文献
1
COVID-19 mRNA vaccine effectiveness (second and first booster dose) against hospitalisation and death during Omicron BA.5 circulation: cohort study based on electronic health records, Portugal, May to July 2022.
Euro Surveill. 2022 Sep;27(37). doi: 10.2807/1560-7917.ES.2022.27.37.2200697.
2
Effectiveness of mRNA COVID-19 vaccines against Omicron and Delta variants in a matched test-negative case-control study among US veterans.
BMJ Open. 2022 Aug 3;12(8):e063935. doi: 10.1136/bmjopen-2022-063935.
3
Effectiveness of 2, 3, and 4 COVID-19 mRNA Vaccine Doses Among Immunocompetent Adults During Periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 Sublineages Predominated - VISION Network, 10 States, December 2021-June 2022.
MMWR Morb Mortal Wkly Rep. 2022 Jul 22;71(29):931-939. doi: 10.15585/mmwr.mm7129e1.
4
COVID-19 vaccine effectiveness against symptomatic SARS-CoV-2 infections, COVID-19 related hospitalizations and deaths, among individuals aged ≥65 years in Portugal: A cohort study based on data-linkage of national registries February-September 2021.
PLoS One. 2022 Sep 13;17(9):e0274008. doi: 10.1371/journal.pone.0274008. eCollection 2022.
5
Comparative Effectiveness of COVID-19 Vaccines in Preventing Infections and Disease Progression from SARS-CoV-2 Omicron BA.5 and BA.2, Portugal.
Emerg Infect Dis. 2023 Mar;29(3):569-575. doi: 10.3201/eid2903.221367. Epub 2023 Feb 3.
6
Effectiveness of a Second COVID-19 Vaccine Booster Dose Against Infection, Hospitalization, or Death Among Nursing Home Residents - 19 States, March 29-July 25, 2022.
MMWR Morb Mortal Wkly Rep. 2022 Sep 30;71(39):1235-1238. doi: 10.15585/mmwr.mm7139a2.
7
Relative effectiveness of a 2nd booster dose of COVID-19 mRNA vaccine up to four months post administration in individuals aged 80 years or more in Italy: A retrospective matched cohort study.
Vaccine. 2023 Jan 4;41(1):76-84. doi: 10.1016/j.vaccine.2022.11.013. Epub 2022 Nov 14.
8
Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Omicron-dominant circulation: I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021 to 2022.
Euro Surveill. 2023 Nov;28(47). doi: 10.2807/1560-7917.ES.2023.28.47.2300187.
9
Analysis of COVID-19 Incidence and Severity Among Adults Vaccinated With 2-Dose mRNA COVID-19 or Inactivated SARS-CoV-2 Vaccines With and Without Boosters in Singapore.
JAMA Netw Open. 2022 Aug 1;5(8):e2228900. doi: 10.1001/jamanetworkopen.2022.28900.
10
Effectiveness of Homologous and Heterologous COVID-19 Booster Doses Following 1 Ad.26.COV2.S (Janssen [Johnson & Johnson]) Vaccine Dose Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults - VISION Network, 10 States, December 2021-March 2022.
MMWR Morb Mortal Wkly Rep. 2022 Apr 1;71(13):495-502. doi: 10.15585/mmwr.mm7113e2.
引用本文的文献
1
Long term bivalent mRNA vaccine effectiveness against COVID-19 hospitalisations and deaths in Portugal: a cohort study based on electronic health records.
BMC Infect Dis. 2025 Apr 23;25(1):590. doi: 10.1186/s12879-025-10866-x.
2
Comparison of two methods for the estimation of COVID-19 vaccine effectiveness of the autumnal booster within the VEBIS-EHR network in 2022/23.
Epidemiol Infect. 2025 Mar 17;153:e54. doi: 10.1017/S0950268825000317.
3
COVID-19 Vaccine Effectiveness of Booster Doses Against Delta and Omicron Variants Over Follow-up Times Using Longitudinal Meta-analysis.
J Res Health Sci. 2024 Sep 30;24(4):e00626. doi: 10.34172/jrhs.2024.161.
4
The impact of the COVID-19 vaccination programme on symptomatic and severe SARS-CoV-2 infection during a period of Omicron variant dominance in Ireland, December 2021 to March 2023.
Euro Surveill. 2024 Jul;29(28). doi: 10.2807/1560-7917.ES.2024.29.28.2300697.
5
Estimating All-Cause Deaths Averted in the First Two Years of the COVID-19 Vaccination Campaign in Italy.
Vaccines (Basel). 2024 Apr 13;12(4):413. doi: 10.3390/vaccines12040413.
6
Effectiveness of XBB.1.5 Monovalent COVID-19 Vaccines During a Period of XBB.1.5 Dominance in EU/EEA Countries, October to November 2023: A VEBIS-EHR Network Study.
Influenza Other Respir Viruses. 2024 Apr;18(4):e13292. doi: 10.1111/irv.13292.
7
Design and analysis heterogeneity in observational studies of COVID-19 booster effectiveness: A review and case study.
Sci Adv. 2023 Dec 22;9(51):eadj3747. doi: 10.1126/sciadv.adj3747. Epub 2023 Dec 20.
8
Effectiveness of the second COVID-19 booster against Omicron: a large-scale cohort study in Chile.
Nat Commun. 2023 Oct 27;14(1):6836. doi: 10.1038/s41467-023-41942-y.
9
Study of efficacy and antibody duration to fourth-dose booster of Ad5-nCoV or inactivated SARS-CoV-2 vaccine in Chinese adults: a prospective cohort study.
Front Immunol. 2023 Sep 6;14:1244373. doi: 10.3389/fimmu.2023.1244373. eCollection 2023.
10
Design and Analysis Heterogeneity in Observational Studies of COVID-19 Booster Effectiveness: A Review and Case Study.
medRxiv. 2023 Jun 28:2023.06.22.23291692. doi: 10.1101/2023.06.22.23291692.
本文引用的文献
1
Estimation of COVID-19 vaccine effectiveness against hospitalisation in individuals aged ≥ 65 years using electronic health registries; a pilot study in four EU/EEA countries, October 2021 to March 2022.
Euro Surveill. 2022 Jul;27(30). doi: 10.2807/1560-7917.ES.2022.27.30.2200551.
2
Effectiveness of 2, 3, and 4 COVID-19 mRNA Vaccine Doses Among Immunocompetent Adults During Periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 Sublineages Predominated - VISION Network, 10 States, December 2021-June 2022.
MMWR Morb Mortal Wkly Rep. 2022 Jul 22;71(29):931-939. doi: 10.15585/mmwr.mm7129e1.
3
Effectiveness of a fourth dose of mRNA COVID-19 vaccine against all-cause mortality in long-term care facility residents and in the oldest old: A nationwide, retrospective cohort study in Sweden.
Lancet Reg Health Eur. 2022 Oct;21:100466. doi: 10.1016/j.lanepe.2022.100466. Epub 2022 Jul 13.
4
Effectiveness of a fourth dose of covid-19 mRNA vaccine against the omicron variant among long term care residents in Ontario, Canada: test negative design study.
BMJ. 2022 Jul 6;378:e071502. doi: 10.1136/bmj-2022-071502.
5
Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting.
N Engl J Med. 2022 Apr 28;386(17):1603-1614. doi: 10.1056/NEJMoa2201688. Epub 2022 Apr 13.
6
mRNA vaccine effectiveness against COVID-19-related hospitalisations and deaths in older adults: a cohort study based on data linkage of national health registries in Portugal, February to August 2021.
Euro Surveill. 2021 Sep;26(38). doi: 10.2807/1560-7917.ES.2021.26.38.2100833.
7
The Portuguese version of the European Deprivation Index: Development and association with all-cause mortality.
PLoS One. 2018 Dec 5;13(12):e0208320. doi: 10.1371/journal.pone.0208320. eCollection 2018.
Zotero 插件